中文摘要：

目的评价中医药治疗糖尿病肾病合并血脂异常的有效性与安全性。方法通过系统检索,收集中医药治疗糖尿病肾病合并血脂异常的随机对照试验,按纳入与排除标准筛选文献、提取资料并评价纳入研究方法学质量后,用Rev Man软件进行Meta分析。结果纳入9篇文献,共585例患者,其中试验组303例,对照组282例。与对照组相比,中医药治疗能降低糖尿病肾病合并血脂异常患者总胆固醇（TC）[MD=-1.02,95%CI（-1.47,-0.57）,P〈0.05],降低甘油三酯（TG）[MD=-0.81,95%CI（-1.22,-0.39）,P〈0.05],降低低密度脂蛋白胆固醇（LDL-C）[MD=-0.59,95%CI（-0.89,-0.30）,P〈0.05];在升高高密度脂蛋白胆固醇（HDL-C）方面差异无统计学意义[MD=0.37,95%CI（-012,0.86）,P〉0.05]。结论中医药在降低糖尿病肾病合并血脂异常患者TC、TG、LDL-C方面与西药相比具有优势。

英文摘要：

Objective To evaluate the efficacy and safety of TCM therapy on diabetic kidney disease complicated with dyslipidemias.Methods All randomized controlled trails（ RCTs） of TCM therapy in treating diabetic kidney disease complicated with dyslipidemias were collected. After literature screening,data extraction and evaluation of the quality of the included research methods according to the Cochrane risk of bias,Revman was used to do meta-analysis. Results 9 literatures were identified involving 585 patients including303 patients in the experimental group and 282 patients in the control group. TCM therapy could lower serum total cholesterol（ TC）[MD =- 1. 02,95% CI（- 1. 47,- 0. 57）,P 0. 05],total triglyceride（ TG） [MD =- 0. 81,95% CI（- 1. 22,- 0. 39）,P 0. 05],low-density lipoprotein cholesterol（ LDL-C） [MD =- 0. 59,95% CI（- 0. 89,- 0. 30）,P 0. 05]. But there was no statistically significance for lowering high density lipoprotein cholesterol（ HDL-C） [MD = 0. 37,95% CI（- 012,0. 86）,P 0. 05] compared with control therapy alone. Conclusion The results of Meta analysis shows that TCM therapy can significantly reduce TC,TG,and LDC-C in diabetic kidney disease complicated with dyslipidemias which has more advantages than western medicine.